1445 related articles for article (PubMed ID: 28765325)
1. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
2. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
[TBL] [Abstract][Full Text] [Related]
3. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
[TBL] [Abstract][Full Text] [Related]
4.
Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
[TBL] [Abstract][Full Text] [Related]
7. Tumor
Afghahi A; Timms KM; Vinayak S; Jensen KC; Kurian AW; Carlson RW; Chang PJ; Schackmann E; Hartman AR; Ford JM; Telli ML
Clin Cancer Res; 2017 Jul; 23(13):3365-3370. PubMed ID: 28087643
[No Abstract] [Full Text] [Related]
8. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Simmons AD; Nguyen M; Pintus E
BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 reversion mutations in a pan-cancer cohort.
Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H
Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241
[TBL] [Abstract][Full Text] [Related]
11. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
12. Identification of Somatically Acquired
Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
[TBL] [Abstract][Full Text] [Related]
13. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
14.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
15. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Patterns of
Arakelyan A; Melkonyan A; Hakobyan S; Boyarskih U; Simonyan A; Nersisyan L; Nikoghosyan M; Filipenko M; Binder H
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525353
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
20. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]